Therefore, we evaluated the impact of both genetic and pharmacological ablation of 5-HT2B in the well-established Notch1+/- mouse model of CAVD, based on the heritable form in patients with NOTCH1 mutations [21–25]. This evidence concerns the gene NOTCH1 and congenital bilateral aplasia of vas deferens from CFTR mutation.